Viela Bio to Report Fourth Quarter and Full Year 2020 Operating and Financial Results on March 1, 2021
Viela Bio (Nasdaq: VIE) announced it will release its fourth quarter and full year 2020 financial results on March 1, 2021, after market close.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Viela Bio (Nasdaq: VIE) announced it will release its fourth quarter and full year 2020 financial results on March 1, 2021, after market close. The company is currently involved in a merger with Horizon Therapeutics, announced on February 1, 2021. As a result, Viela will not hold a conference call for the earnings report. Relevant materials will be available on the company's Investor Relations page. Viela Bio focuses on developing treatments for autoimmune and severe inflammatory diseases.
Details
News Market Reaction – VIE
The recorded move for VIE in the trading session of this news was -0.18%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
GAITHERSBURG, Md., Feb. 22, 2021 (GLOBE NEWSWIRE) -- Viela Bio (Nasdaq:VIE), a biotechnology company dedicated to the discovery, development and commercialization of novel treatments for patients suffering from autoimmune and severe inflammatory diseases, today announced it will report its fourth quarter and full year 2020 operating and financial results after the U.S. financial markets close on Monday, March 1, 2021.
In light of the agreement and plan of merger by and among Viela Bio, Horizon Therapeutics, Inc., Teiripic Merger Sub, Inc., and Horizon Therapeutics plc, announced on February 1, 2021, Viela will not be hosting a conference call for its fourth quarter 2020 results. Earnings materials will be made available publicly on the Investor Relations page of Viela’s website at www.vielabio.com.
About Viela Bio
Viela Bio, headquartered in Gaithersburg, Maryland, is a biotechnology company dedicated to the discovery, development and commercialization of novel treatments for patients suffering from autoimmune and severe inflammatory diseases. For more information, please visit www.vielabio.com.
Source: Viela Bio
Contacts:
Investors:
Solebury Trout
Chad Rubin
646-378-2947
crubin@soleburytrout.com
Media:
Solebury Trout
Amy Bonanno
914-450-0349
abonanno@soleburytrout.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.